Nakul M. Shah

Antibody–drug conjugates in solid tumors: Efficacy, challenges, and opportunities

Nakul M. Shah, Funda Meric‐Bernstam

Antibody-drug conjugates (ADCs) have become an increasingly important component of the therapeutic landscape of many solid tumors. Currently, there are eight ADCs approved for solid tumors, with hundreds being developed and in clinical trials. Initially being approved in the advanced or metastatic …

us (code pays fourni par la source)

9Therapeutic Targeting of the KRAS in BTC Background

Farinaz Barghi, Ming Zhao, Erkan Yuca, Kurt Evans et autres

Abstract Background KRAS mutations are highly prevalent in biliary tract cancer (BTC), including cholangiocarcinoma (CCA), underscoring the need for KRAS-targeted therapies. While KRAS G12C mutations are rare (6%), the more common G12D (41%) and G12V (23%) variants warrant investigation. TROP2-targeted antibody–drug conjugates …

us (code pays fourni par la source)

Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65

Pawan Upadhyay, Jeremy T. Beales, Nakul M. Shah, Agata Gruszczynska et autres

us (code pays fourni par la source)

Abstract 3075: FGFR2b is a highly prevalent and actionable cell surface target in intrahepatic cholangiocarcinoma

Nakul M. Shah, Beatriz Alvarado-Hernandez, Xi Chen, Quentin Kimana et autres

Abstract Intrahepatic cholangiocarcinoma (iCCA) is an aggressive type of biliary tract cancer (BTC) with a rising incidence and limited treatment options. Previously established cell-surface targets of antibody-based therapies are not common in iCCA; for example, HER2 amplification occurs in <5% of patients. …

us (code pays fourni par la source)

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities

Leming M. Shi, Xi Jin, Wei Huang, François Bertucci et autres

us (code pays fourni par la source)

The present and future of precision oncology and tumor-agnostic therapeutic approaches

Nakul M. Shah, Funda Meric‐Bernstam

Precision oncology has transformed the treatment landscape for patients with advanced solid tumors. Tumor-agnostic therapies, those that have been approved based on genetic mutations or biomarkers across tumor histology types, are important examples of how the implementation of precision oncology can expand …

us (code pays fourni par la source)

MePCE promotes homologous recombination through coordinating R-loop resolution at DNA double-stranded breaks

Sravan K. Devanathan, Yi-Ru Li, Samantha B. Shelton, Wei-Che Tseng et autres

MePCE is a multifunctional protein that regulates the positive transcription elongation factor b (P-TEFb) partitioning between the nucleosol and chromatin. MePCE's role in sequestering P-TEFb in the nucleosol via the 7SK ribonuclear protein complex (RNPc) is clear, but its functions on chromatin …

us (code pays fourni par la source)

Integrative Molecular and Functional Analysis of Human Sperm Subpopulations to Identify New Biomarkers of Fertilization Potential

Pedro Caballero-Campo, Saúl Lira-Albarrán, Alexandra Amaral, Chibo Hong et autres

mx, us, pt, ca (code pays fourni par la source)

EPCO-08. EPIGENETIC THERAPY POTENTIATES TRANSPOSABLE ELEMENT TRANSCRIPTION TO CREATE TUMOR-ENRICHED ANTIGENS IN GLIOBLASTOMA

H. Josh Jang, Nakul M. Shah, Ju Heon Maeng, Yonghao Liang et autres

Abstract Epigenetic treatment has been studied as a means to augment anti-tumor immune cell activity by increasing the expression of antiviral response genes. Previous studies, including our own, have revealed an additional consequence of epigenetic treatment: reactivation of transposable elements (TEs). Normally, …

us (code pays fourni par la source)

Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells

H. Josh Jang, Nakul M. Shah, Ju Heon Maeng, Yonghao Liang et autres

us (code pays fourni par la source)

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities

Yi‐Zhou Jiang, Ding Ma, Xi Jin, Yi Xiao et autres

cn, us, fr (code pays fourni par la source)

Integrated molecular portraits of breast cancer

Yi‐Zhou Jiang, Ding Ma, Xi Jin, Yi Xiao et autres